Not enough data
Eliza Slawther's articles predominantly focus on legal policy regulation and government announcements within the healthcare and pharmaceutical industry. Her coverage revolves around institutions such as EMA (European Medicines Agency) and FDA (Food and Drug Administration), with a specific emphasis on drug development, AI regulation, and their impacts.
Given her emphasis on government announcements and regulatory developments in the pharma industry, she would likely be interested in pitches from experts who can provide analysis or commentary about new regulations, policies, or major decisions made by these agencies. Sources well-versed in the workings of EMA, FDA, drug approval processes or AI applications in healthcare are likely to attract her attention.
As Eliza's geographic focus is not specified but given the nature of her coverage related to European agencies like EMA along with global entities like FDA suggests an international outlook for potential stories.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: May By, Eliza Slawther
The Council of the EU and the European Parliament have reached a provisional agreement on the draft Critical Medicines Act. Orphan drugs are set to be included in its scope – a move that has raised concern for the industry trade group, EUCOPE.
By: May By, Eliza Slawther
Pharmaceutical companies should ensure they have the right operational model to address the challenges of preparing for joint clinical assessments under the EU Health Technology Assessment Regulation, and perform a “dry run” ahead of time, a market access consultancy CEO advises.
By: Eliza Slawther, May By
New draft guidelines on company mergers published by the European Commission seek to protect innovation, a move that could be helpful for pharma companies and investors, a lawyer says.
By: May By, Eliza Slawther
The upcoming EU Biotech Act could be improved by taking more ambitious measures on clinical trial approval timelines to reverse Europe's declining clinical trial activity, according to Alexion's Soraya Bekkali.
By: Eliza Slawther, May By
Existing antiviral medicines, such as Gilead's COVID-19 drug Veklury, could potentially be repurposed to combat the Ebola disease outbreak caused by the Bundibugyo virus, the European Medicines Agency says.
By: May By, Eliza Slawther
Extending the scope of supplementary protection certificates under the EU Biotech Act could be a “strong magnet” for R&D investment in Europe, but the current draft legislation is too narrow and should be broadened to cover a range of innovative products, a senior Alexion executive says.
By: May By, Eliza Slawther
The Australian Therapeutic Goods Administration plans to continue its focus on reforming its prescription medicines registration process, reviewing its medicines repurposing program and supporting the use of animal-free testing methods after reflecting on the 2024-2025 financial year.
By: May By, Eliza Slawther
The Coalition for Epidemic Preparedness Innovations is mobilizing multiple strategies to support rapid vaccine development against the Bundibugyo virus, including the establishment of a common antibody benchmark for developers.
By: Jun By, Eliza Slawther
Simplifications to the regulatory structure in the EU as proposed in the upcoming Biotech Act could yield direct cost savings of up to $3.1bn per year for sponsors, according to a European Commission report.
By: Jun By, Eliza Slawther
The Swiss healthcare products regulator has secured a funding increase worth nearly $3.4m from the country's Federal Council for 2027 as part of a plan to address its “precarious” financial situation – but the money is contingent on staff reductions and operational cuts.
